Tag Archives: Pharma Companies

Top Pharma News and Developments that Made Headlines in July

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Amgen signs collaboration agreement with Array BioPharma

2000px-amgen-svg

Amgen and Array BioPharma announced a preclinical license and collaboration agreement in inflammation.

Under the agreement, the two companies will collaborate on the discovery and development of new drugs for autoimmune disorders. Amgen will be responsible for clinical development and commercialization, having exclusive rights to Array’s preclinical program. In turn, upfront and milestone payments will be made by Amgen.

 

Bavarian Nordic partnered with Johnson & Johnson for HIV, HBV shots

j-j-logo

Danish company Bavarian Nordic and Johnson & Johnson have signed a deal worth USD 879M  to develop HIV, HBV shots.

Under the terms of the deal, Bavarian Nordic is granting J&J’s Janssen unit the rights to combine MVA-BN with Janssen’s own AdVac platform in the HIV and HBV programs. In return, Janssen will pay Bavarian Nordic $10 million upfront and up to $836 million in milestones. Bavarian Nordic will design, produce and deliver the MVA needed, while Janssen will handle R&D.

 

Samsung and Merck launched Remicade biosim

merck_logo

Samsung and Merck & Co. launched Renflexis in the US. Renflexis is 35% cheaper than J&J’s anti-inflammatory med.

Last year, Pfizer launched its version, Inflectra, at a 15% discount. Renflexis is the third biosim to launch in the US after Inflectra and Sandoz’s Zarxio, a biosimilar to Amgen’s Neupogen.

 

Gilead’s Vosevi got US FDA Approval

gilead

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.

The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated Vosevi during an interval of 12 weeks.

 

Novo Nordisk and Glooko launch co-marketed app

novo_nordisk-logo

As a result of Novo Nordisk’s partnership with diabetes health tech startup Glooko a new app was launched. It’s dubbed Cornerstones4Care Powered by Glooko, or the C4C app.

The app allows diabetes patients to measure and track blood glucose, activities and meals. It syncs blood glucose and activity data from a wide array of diabetes or exercise devices.

The app is free for registered C4C online users and can be downloaded from the Apple or Google app stores.

 

AstraZeneca partners with Merck to develop and commercialise cancer drugs

astrazeneca-svg

AstraZeneca and Merck & Co have entered a global oncology collaboration to co-develop and co-commercialise the AstraZeneca’s Lynparza and selumetinib for various cancer types.

Under the agreement, the companies will develop and commercialise Lynparza jointly, as monotherapy and in combination with other potential medicines. Furthermore, they will develop and commercialise Lynparza in combination with their own PD-L1 and PD-1 medicines, Imfinzi and Keytruda.

AstraZeneca and Merck will also co-develop and commercialise selumetinib, the former’s selective inhibitor of MEK, that’s being developed for several indications including thyroid cancer.

The 2 companies will share development and commercialisation costs as well as profits from product sales.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

 

Advertisements

How 6 Big Pharma Companies Use Twitter to Engage with Audiences

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Pharma companies have begun to embrace different communication channels, including social media, to promote their products, present their drug development initiatives and engage with audiences worldwide.

However, make no mistake, social media is not the same for pharma companies as it is for regular users. Without proper planning, controls and staff training, firms risk fines, sanctions and worse, damage to their reputation.

Facebook, Twitter and Pinterest are the main online networks that pharmaceutical companies are eyeing. In this article, we’ll take a look at how pharma companies like Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis use Twitter to maintain a close connection with their existing and potential patients.

 

Bristol-Myers Squibb

Screen Shot 2017-06-13 at 09.23.23

@bmsnews is the name of New York-based Bristol-Myers Squibb’s Twitter account. The latter was opened in April 2009 and has now has 108.000 followers. The company’s Twitter feed covers everything from drug research results and analysis, clinical collaborations with other pharma companies, to features about the company’s supply chain, and many more.

 

AstraZeneca

Screen Shot 2017-06-13 at 09.24.44

Apart from the main @AstraZeneca Twitter account, the company also has accounts for different countries (UK, US, Canada, etc) and a Twitter profile dubbed @AZhelps. The latter is destined to help people manage and support their health more confidently. The account was opened in 2009 and it currently has over 3000 followers. On the official company account, AstraZeneca posts articles and press releases related to drug discovery, tweets from different conferences, research data, etc. The account now boasts 126.000 followers.

 

GlaxoSmithKline

Screen Shot 2017-06-13 at 09.26.15

@GSK was one of the first pharma companies to be on Twitter. They created their account 10 years ago, in 2007, and now have 146.000 followers. The UK-based company also has a US version @GSKUS that it started in March 2009 and has 73.800 followers. They post R&D updates, info about conferences and events that they’re attending, studies, interviews with patients and employees, etc.

 

Pfizer

Screen Shot 2017-06-13 at 09.27.12

Apart from having separate Twitter accounts for countries like Belgium, France, Turkey, Germany, Austria, etc, @pfizer has an official Twitter profile started in 2009 which now has 206.000 followers and a channel dedicated to media announcements and investor communications dubbed @pfizer_news. Pfizer’s Twitter account is the most followed of all the big pharma Twitter accounts. It mainly focuses on the company’s initiatives in the greater therapeutic arena (like the #QuitSmoking one), cancer research, health tips, polls and surveys, etc.

 

Sanofi

Screen Shot 2017-06-13 at 09.28.33

@sanofi created its official Twitter profile in 2009 and now has 92.600 followers. The French pharma company has more than 18 Twitter accounts. It has handles for different regions – France, Canada, and the US, as well as accounts for different units like its diabetes franchise and its Genzyme unit. On the company’s official Twitter feed you can find posts related to Big Data and health initiatives, collaborations with startups to develop new health solutions, their anti counterfeiting initiatives, vaccines research and development, etc.

 

Novartis

Similar to the other pharma companies, Novartis has several Twitter handles, one for each division of the company (@NovartisPharma for the pharmaceutical division, @NovartisScience, @NovartisCancer) as well as the official page @Novartis. The latter was created in 2008 and has 216.000 followers.

Also, Novartis has one account devoted entirely to oncology clinical trials @NovartisOncCT that allows patients to find out if they qualify for trials.

On their general Twitter account, they update their audience on the latest drug research and development initiatives, post news related to partnerships and collaborations, etc.

Screen Shot 2017-06-13 at 09.29.44

In June 2014, the FDA released its social media guidance regarding the presentation of risk and benefit information which prevents pharma companies from marketing their drugs on social media without presenting the risks associated with their use. However, pharma players have found creative and useful ways of attracting and keeping their audiences engaged. Chapeau!

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News and Developments that Made Headlines in May

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Merck’s Keytruda got FDA approval to treat genetically ID’d tumors

merck_logo

Merck’s Keytruda was approved by the FDA to treat patients whose cancers have a specific genetic feature, making that the first time the FDA approved a cancer treatment based on a common genetic feature and not on the location where the tumor originated.

Keytruda is used for the treatment of solid tumors that have a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

 

The FDA approved first generic Strattera for the treatment of ADHD

The first generic versions of Strattera  have been approved by the FDA to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

fda

Strattera will be marketed by Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited.

 

Bristol-Myers Squibb entered strategic collaboration with Array BioPharma

bms

Bristol-Myers Squibb has entered a clinical research collaboration with Array BioPharma to test the latter’s investigational MEK inhibitor, binimetinib in combination with its Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen. This could be a treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.

Bristol-Myers Squibb’s Opdivo has recently been accepted for priority review in liver cancer.

 

Sanofi and Regeneron Got FDA Approval for Kevzara

Impression

Sanofi and Regeneron announced FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patientswho have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).

Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signaling. IL-6 is a cytokine in the body that, in excess and over time, can contribute to the inflammation associated with RA.

In the US, Kevzara will be marketed by Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi.

 

Novartis receives FDA approval for expanded use of Zykadia

novartis

The US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

Zykadia first received accelerated approval in 2014 for patients with ALK-positive metastatic NSCLC who progressed on or are intolerant to crizotinib.

In January 2017, the FDA granted Zykadia Breakthrough Therapy designation for the first-line treatment of patients with ALK-positive metastatic NSCLC with metastases to the brain, and Priority Review for first-line ALK-positive metastatic NSCLC.

 

AstraZeneca’s Imfinzi was shown to reduce the risk of disease worsening or death in the Phase III PACIFIC trial

astrazeneca-svg

AstraZeneca and MedImmune, its global biologics research and development arm, revealed positive results for the Phase III PACIFIC trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy combined with radiation therapy.

AstraZeneca also received accelerated approval from the US FDA for Imfinzi in previously treated patients with advanced bladder cancer.

 

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News and Developments that Made Headlines in April

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

FDA approved Brineura for a specific form of Batten disease

fda

The U.S. Food and Drug Administration approved Brineura as a treatment for a specific form of Batten disease. Being an enzyme replacement therapy, Brineura’s active ingredient (cerliponase alfa) is a recombinant form of human TPP1, the enzyme deficient in patients with CLN2 disease.

Brineura is set to slow loss of walking ability in pediatric patients aged 3 and older suffering from late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency.

The FDA granted approval of Brineura to BioMarin Pharmaceutical Inc.

 

Novartis entered clinical trial agreement with Allergan

novartis

Novartis entered into a clinical trial agreement with Allergan to use its FXR agonist and Allergan’s cenicriviroc (CVC) for the treatment of non-alcoholic steatohepatitis (NASH) as part of a Phase IIb study.

NASH is known to be one of the biggest triggers of liver diseases leading to liver transplants worldwide. At the moment, there aren’t any approved treatments for NASH.

As part of the agreement, Novartis and Allergan will conduct a Phase IIb clinical trial to assess the safety, efficacy and tolerability of their combines therapies for NASH.

 

Bristol-Myers Squibb enters into separate agreements with Biogen & Roche

bms

Bristol-Myers Squibb entered into two separate agreements with Biogen and Roche to License anti-eTau and anti-myostatin compounds.

Under the agreements, Bristol- Myers Squibb plans to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to Biogen, and BMS-986089, an anti-myostatin adnectin in development for Duchenne Muscular Dystrophy, to Roche.

 

Roche’s Tecentriq won FDA OK

roche

Genentech, a unit of Swiss drugmaker Roche Holding AG, got approval from the FDA for its already approved immunotherapy drug, Tecentriq, to treat advanced bladder cancer. The FDA granted Tecentriq an accelerated approval as an initial treatment for patients with advanced bladder cancer who are not eligible for standard cisplatin chemotherapy.

Tecentriq belongs to PD-1 inhibitors drug class. The latter helps the immune system fight cancer by blocking a mechanism used by tumors to escape attack.

 

GlaxoSmithKline’s malaria vaccine Mosquirix to undergo pilot studies in Ghana, Kenya and Malawi

gsk

GlaxoSmithKline’s Mosquirix is set to undergo real-world pilot studies in Ghana, Kenya and Malawi, 3 African countries selected by the World Health Organization, starting next year.

The pilots will enroll babies aged between 5 to 17 months. Besides testing the vaccine’s efficacy, the study will also focus upon whether it’s possible or not to deliver 4 doses in the sub-Saharan areas.

World Health Organization selected the three African countries because of their high malaria rates despite broad use of insecticidal bed nets and well-functioning immunization programs.

 

Takeda partners Harrington Discovery Institute for rare disease therapeutics development

Takeda

Pharma company Takeda has partnered with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, to advance breakthrough therapeutic discoveries in rare diseases.

Under the agreement, Takeda will leverage Harrington Discovery Institute’s established operating model to set up a new programme to advance the development of medicines for rare diseases.

The Harrington programme will assist US MD and PhD researchers to carry out disruptive and transformative research, that may lead to the development of new treatments.
cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

Deep Learning in Drug Discovery & Companies That Provide It

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

In order to better understand the meaning of deep learning, we first need to take a look at big data.

 

Big Data

New technologies such as the internet of things (IoT) and genomics generate huge data sets in a completely unstructured manner which are referred to as big data. These data sets are so large and so complex that they can’t be analysed using traditional apps and software. Therefore, new applications emerge. One of the biggest players in the field is Palantir Technologies, a company which helps make sense of all this big data. While storing this data is one thing, analyzing it is something completely different and it takes us to the concept of deep learning.

 

Deep Learning

Deep learning involves teaching a computer to make sense of all the unstructured big data using various methods like “artificial neural networks” which mimic the way the human brain works. What it does is use algorithms to search for complex relationships in all that “big data.”Those algorithms are constantly refined and improved.

Cognitive computing refers to a computer’s ability to learn more over time based on experience, much like the human brain does. You’ve probably read some articles on IBM’s Watson cognitive computing platform that uses deep learning for translation, speech-to-text, and text-to-speech. Deep learning or cognitive computing is a form of artificial intelligence.

Deep Learning & Drug Discovery

As explained so far, deep learning is a way to analyse big data and find relationships within huge data sets that would take years and years for humans to discover and process on their own.

If we see this in the context of the drug discovery industry, many years of research are needed to identify a drug compound that might be effective in combating a disease prior to seeking FDA approval. The FDA approval process is actually more like the cherry on top, it comes after huge research and extended trials. All this translates into billions spent by the pharmaceutical industry

on R&D with the aim of discovering compounds that treat specific diseases. Unfortunately, the path is long and rocky leading to only a fraction of all that research translated into commercial drugs.

Deep learning could make things faster and much more efficient by analysing a wide spectrum of already effective molecular compounds and use the findings to develop new drugs to combat diseases.

Some companies have turned to deep learning in an attempt to shorten the drug discovery cycle by building platforms that enable the discovery of new drug compounds, while predicting their likely success.

 

Atomwise

Founded in 2012, US-based deep learning company Atomwise is the creator of AtomNet, the first deep learning technology for novel small molecule discovery, characterized by its unprecedented speed, accuracy, and diversity. The company has worked with companies like Merck and has been involved in Ebola treatment research.

 

Insilico Medicine

Founded in 2014, Insilico Medicine raised USD 10M in a venture round in February 2017. The company is dedicated to finding novel solutions for cancer, aging and age-related diseases using advances in genomics and big data analysis. They provide services like advanced deep learning, custom drug and biomarkers discovery, aging research tools to academia, pharma and cosmetics companies.

 

Berg Health

Berg Health is a Boston-based biopharma company founded in 2006. They use their “Berg Interrogative Biology™ discovery platform” to reduce the time, and expense, of drug development. Berg focuses on three distinct areas: diagnostics, pharmaceutical research and development and health care analytics.

 

twoXAR

Founded in 2014, twoXAR is “an artificial intelligence-driven drug discovery company.” Using its computational platform, twoXAR identifies promising drug candidates, lowers risks through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships. Their DUMA Drug Discovery platform evaluates enormous datasets to identify and rank high probability drug-disease matches in minutes rather than years.

Using deep learning for drug discovery is still in its early stages but it definitely shows great promise. By teaching a computer how to learn, relationships between vast data sets are uncovered thus helping scientists and researchers learn more about how to treat diseases whether they’re new or have been around for decades.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

5 Blockbuster Drugs of 2016 & the Companies Behind Them

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Before tapping into some of last year’s blockbuster drugs, let’s first remember or find out what the first blockbuster treatment was. Its name was Tagamet and it was developed by Smith, Kline and French (now part of GlaxoSmithKline). The drug hit the market in 1976 and it treated ulcers and gastrointestinal problems. During its 17 years of patent protection, the drug generated USD 14 billion. That may not seem a large sum this year but back in the days Tagamet’s revenues were pretty impressive.

Coming back to 2016, these are a few of the blockbuster drugs that made headlines last year:

 

Tenofovir alafenamide and emtricitabine and rilpivirine (R/F/TAF)

Developed by Gilead Sciences and Janssen R&D, R/F/TAF is used for HIV-1 infection. Gilead’s TAF-based combination therapy in partnership with Johnson & Johnson’s Janssen unit is set to improve renal and bone mineral density measurements, as well as longevity of HIV patients. The increased numbers of those eligible for antiretroviral drugs translates into a large market for the two new TAF-based drugs. The sales forecast for 2020 is USD 1.57 billion.

 

Merck & Co’s MK-5172

MK-5172, otherwise known as Grazoprevir, is a drug developed by Merck and approved for the treatment of hepatitis C. It completed Phase III trials used in combination with the NS5A replication complex inhibitor elbasvir under the trade name Zepatier.

On the market for hepatitis C treatments, Merck’s drug goes up against Gilead’s Harvoni and Abbvie’s Viekira Pak. MK-5172’s sales forecast for 2020 is USD 1.54 billion.

 

ACADIA Pharmaceuticals’ Nuplazid

In April 2016, Pimavanserin (Nuplazid, Acadia Pharmaceuticals) received FDA approval for the treatment of Parkinson’s disease psychosis (hallucinations and delusions). The FDA named Pimavanserin a breakthrough therapy for this condition, being the first medication to receive approval for this indication. The drug works by targeting 5-HT2A receptors that are believed to play an important part in Parkinson’s disease psychosis. The FDA approval was based on data from a phase 3 Study-020 and other studies that add up to the largest research program in Parkinson’s disease psychosis. Nuplazid’s sales forecast for 2020 is USD 1.41 billion.

 

Nippon Shinyaku & Actelion’s Uptravi (selexipag)

Uptravi (selexipag) was originally discovered and synthesized by Nippon Shinyaku for the treatment of pulmonary arterial hypertension (PAH).  Uptravi was approved by the health authorities in the US and Europe, based on clinical data of the phase 3 study (GRIPHON study), conducted by Actelion, Nippon Shinyaku’s global partner. The drug entered the market in the first week of January 2016 and its sales forecast for 2020 is already USD 1.27 billion.

 

Genentech’s Atezolizumab (Tecentriq)

Tecentriq is the first in its class of drugs, PD-1/PD-L1 inhibitors, approved to treat the most common type of bladder cancer, otherwise knows as urothelial carcinoma. In May 2016, The FDA approved Tecentriq for treatment of patients with locally advanced or metastatic urothelial carcinoma whose condition showed no improvement during or following platinum-containing chemotherapy. By 2020, Tecentriq could hit USD 2.5 billion in sales.

Some experts say that the age of blockbuster drugs is coming to an end. Among the reasons stated are the new regulatory and pricing models but also the fact that medications have got better and better so new drugs don’t just have to be effective, they have to be superior to what already exists on the market. That may trigger a change in business models and strategies for pharma companies in 2017 and beyond.

 

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses this year are:

A Closer Look at the Top 5 Largest Pharma Companies in the World

If you google “pharma news” you’ll find an impressive number of websites dedicated to the latest news in the pharma industry, covering an impressive number of players, some new, others well-established. But who are the leaders, the companies that set new directions while changing people’s lives during the process?

Here are some interesting pieces of information on 5 of the largest pharma companies in the world.

 

Johnson & Johnson (J&J)

jnj

Revenue: 70.07 billion USD (2015)

 

Johnson & Johnson is the largest pharma company in the world. It was founded in the US in 1886 by the three Johnson brothers Robert, James, and Edward who initially only focused upon producing antiseptics in order to prevent illness and death. Consequently, Johnson & Johnson was the first company to produce first aid kits, as well as sanitary products for women, dental floss, and commercial dressings for small wounds.

Today, Johnson & Johnson has more than 127,000 employees in over 57 countries. The company’s focus in now upon 3 major areas: pharmaceuticals, diagnostics, and consumer products. J&J has manufactured innovative products Band-Aid, Tylenol, Rogaine, Johnson’s baby products, and Neutrogena skin care.

 

Novartis

novartis

Revenue: 49.41 billion USD (2015)

 

Novartis, the second largest pharmaceutical company in the world, was founded in Switzerland in 1996 following the merger of Ciba-Geigy and Sandoz, two Swiss companies founded over 250 years ago. Novartis is known to be one of the biggest pharma spenders on research, investing over $9.9 billion in R&D.

The company has over 118.000 employees and is currently divided into 3 operating divisions:

Pharmaceuticals, Alcon (eye care) and Sandoz (generics). While its generics business is the second largest in the world, Novartis is number one when it comes to its Its eye care division. Novartis’s best-selling drug is Gleevec which generated sales of USD 4.7 billion in 2015 alone.

 

Pfizer

pfizer

Revenue: 48.85 billion USD (2015)

 

Pfizer was founded in the US in 1849, which makes it one of the oldest pharma companies in the world. The company started very small. It was founded by cousins Charles Pfizer, a chemist, and Charles Erhart, a confectioner, with money borrowed from Pfizer’s father. The two soon developed their first product, an antiparasitic dubbed santonin, that was used to treat intestinal worms. The drug turned out to be a real success.

Pfizer developed many well-known pharmaceutical drugs such as antidepressant Zoloft, lowering blood cholesterol drug Lipitor, and Viagra, a drug used to treat erectile dysfunction. The company has over 78.000 employees and a profit margin that makes it the most profitable pharma company in the world.

 

Roche

roche

Revenue: 50.856 billion USD (2015)

 

The company was founded by Fritz Hoffman-La Roche in Basel, Switzerland in 1896 during the European industrial revolution. During its first years, it successfully produced the first in a series of thyroid medications, as well as a non-prescription cough syrup dubbed Sirolin. After the World Wars, Roche became the first company to mass-produce synthetic vitamin C.

With over 88.000 employees, the company operates two segments – pharmaceuticals and diagnostics – and sells its products in over 190 countries. Roche’s prescription drugs include cancer therapies MabThera/Rituxan and Avastin, Perjeta and Kadcyla for HER2-positive breast cancer, hepatitis drug Pegasys, idiopathic pulmonary fibrosis drug Esbriet, macular degeneration therapy Lucentis, and Tamiflu, which is used to prevent and treat influenza (including pandemic strains).

 

Bayer

bayer

Revenue: 46.32 billion EUR

 

Bayer was founded in Germany in 1863 and it became renowned through its iconic product Aspirin which was developed in 1897. A year later, the company started the commercialization of heroin as a cough suppressant and a substitute for morphine.

Bayer’s lost its assets and trademarks during WW II as part of America’s campaign against Germany. It was only in 1978 that the company brought back its business in the US.

Nowadays, Bayer has over 116,000 employees and its key products include analgesics such as Bayer Aspirin and Aleve, food supplements Redoxon and Berocca, and skincare products Bepanthen and Bepanthol.

These are the top 5 pharma companies that probably everyone has heard of. They are closely followed by Merck, Sanofi, GlaxoSmithKline, AstraZeneca and Gilead Sciences.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: